Bourgeon Capital Management LLC Reduces Stock Position in Pfizer Inc. $PFE

Bourgeon Capital Management LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 48.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 213,288 shares of the biopharmaceutical company’s stock after selling 200,406 shares during the period. Bourgeon Capital Management LLC’s holdings in Pfizer were worth $5,170,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Bessemer Group Inc. grew its position in shares of Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after purchasing an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK lifted its holdings in Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after acquiring an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp acquired a new position in Pfizer in the first quarter valued at approximately $8,283,000. Westbourne Investments Inc. acquired a new position in Pfizer in the first quarter valued at approximately $2,411,000. Finally, Bourne Lent Asset Management Inc. lifted its holdings in Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after acquiring an additional 18,200 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE opened at $23.84 on Tuesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a market capitalization of $135.54 billion, a price-to-earnings ratio of 12.68, a price-to-earnings-growth ratio of 0.77 and a beta of 0.55. The firm has a 50-day simple moving average of $24.54 and a 200-day simple moving average of $24.11. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Bank of America increased their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Morgan Stanley increased their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.